$ROIV

$ROIV ROIVW - Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift…

$ROIV SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ROIV Roivant Sciences Ltd. : $36.54 Sector: Healthcare | YTD: 🔼…

$ROIV Roivant Sciences: Brepocitinib Meets Primary and All Key Secondary Endpoints in Two Phase 3 Trials for Non-Infectious Uveitis, sNDA Planned for…

$ROIV ROIVW - Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU…

$ROIV ROIVW - Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9…

$ROIV ROIVW - Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus…

$ROIV ROIVW - Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial…

$ROIV ROIVW - Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with…

$ROIV ROIVW - Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S…

$ROIV ROIVW - Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S…

$ROIV highs continue off FDA earlier release…

$ROIV SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ROIV Roivant Sciences Ltd. : $36.28 Sector: Healthcare | YTD: 🔼…